NO934315D0 - Farmas!ytisk b{rer - Google Patents

Farmas!ytisk b{rer

Info

Publication number
NO934315D0
NO934315D0 NO934315A NO934315A NO934315D0 NO 934315 D0 NO934315 D0 NO 934315D0 NO 934315 A NO934315 A NO 934315A NO 934315 A NO934315 A NO 934315A NO 934315 D0 NO934315 D0 NO 934315D0
Authority
NO
Norway
Prior art keywords
giving
matrix
inert
active substance
pharmaceutically active
Prior art date
Application number
NO934315A
Other languages
English (en)
Other versions
NO934315L (no
NO306539B1 (no
Inventor
Bror Morein
Karin Loevgren
Original Assignee
Iscovent Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iscovent Ab filed Critical Iscovent Ab
Publication of NO934315D0 publication Critical patent/NO934315D0/no
Publication of NO934315L publication Critical patent/NO934315L/no
Publication of NO306539B1 publication Critical patent/NO306539B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/779—Possessing nanosized particles, powders, flakes, or clusters other than simple atomic impurity doping
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
NO934315A 1991-05-31 1993-11-29 Medikamentbaerende partikkel og farmasöytisk blanding NO306539B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9101665A SE502569C2 (sv) 1991-05-31 1991-05-31 Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
PCT/SE1992/000367 WO1992021331A1 (en) 1991-05-31 1992-06-01 Pharmaceutical carrier

Publications (3)

Publication Number Publication Date
NO934315D0 true NO934315D0 (no) 1993-11-29
NO934315L NO934315L (no) 1994-01-26
NO306539B1 NO306539B1 (no) 1999-11-22

Family

ID=20382906

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934315A NO306539B1 (no) 1991-05-31 1993-11-29 Medikamentbaerende partikkel og farmasöytisk blanding

Country Status (13)

Country Link
US (1) US5603958A (no)
EP (1) EP0587659B1 (no)
JP (1) JPH07500084A (no)
KR (1) KR100227302B1 (no)
AT (1) ATE152620T1 (no)
AU (1) AU680807B2 (no)
CA (1) CA2103447C (no)
DE (1) DE69219600T2 (no)
ES (1) ES2103946T3 (no)
FI (1) FI110408B (no)
NO (1) NO306539B1 (no)
SE (1) SE502569C2 (no)
WO (1) WO1992021331A1 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
WO1998001039A1 (fr) * 1996-07-08 1998-01-15 Idemitsu Materials Co., Ltd. Composition d'alimentation pour volaille
WO1999029320A1 (en) * 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel administration form comprising an acid-labile active compound
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
EP1121088B1 (de) * 1998-10-14 2002-12-18 Cognis Deutschland GmbH & Co. KG Verwendung von nanoskaligen sterolen und sterolestern
HUP0201220A3 (en) * 1999-05-13 2004-07-28 Wyeth Holdings Corp Madison Adjuvant combination formulations
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
EP1377320B1 (en) * 2001-04-04 2008-10-01 Nordic Vaccine Technology A/S Polynucleotide binding complexes comprising sterols and saponins
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
DK1465615T3 (da) * 2002-01-15 2012-11-12 Dartmouth College Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
CA2488617A1 (en) * 2002-06-10 2003-12-18 Eugene R. Cooper Nanoparticulate sterol formulations and sterol combinations
JP2006503072A (ja) * 2002-10-02 2006-01-26 ノルディック ワクチン テクノロジー アクティーゼルスカブ ワクチン接種用組成物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2410587T3 (es) * 2004-01-22 2013-07-02 University Of Miami Formulaciones tópicas de coenzima Q10 y métodos de uso
CN100339083C (zh) * 2004-02-24 2007-09-26 范敏华 一种黄体酮液体胶囊及其制备方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100398151C (zh) * 2005-02-18 2008-07-02 浙江大学 人参皂甙纳米微粒及其制备方法和用途
US20110098177A1 (en) * 2006-03-28 2011-04-28 Novus International Inc. Methods and compositions of plant micronutrients
US8691843B2 (en) * 2006-07-12 2014-04-08 Novus International, Inc. Antioxidant combinations for use in ruminant feed rations
US20080015218A1 (en) * 2006-07-12 2008-01-17 Novus International Inc. Antioxidant combinations for use in ruminant feed rations having a fat source
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
CA2670099A1 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
WO2008061078A2 (en) * 2006-11-17 2008-05-22 Novus International Inc. Matrix-embedded compositions having organic acids and fatty acids
US20080119552A1 (en) * 2006-11-17 2008-05-22 Novus International Inc. Matrix-embedded compositions having organic acids and fatty acids
WO2008064132A2 (en) * 2006-11-17 2008-05-29 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US9040081B2 (en) * 2006-11-20 2015-05-26 Duecom Use of lipid containing particles comprising Quillaja saponins for the treatment of cancer
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
EP2161986A4 (en) * 2007-07-03 2014-06-25 Novus Int Inc FOOD RATIONS FOR PORCLES WITH LOW FERMENTABLE CARBOHYDRATE CONTENT
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
WO2009088879A1 (en) * 2008-01-04 2009-07-16 Novus International Inc. Combinations to improve animal health and performance
CA2711834C (en) 2008-01-11 2017-03-14 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
CN103462896A (zh) 2008-04-11 2013-12-25 细胞研究有限公司 诱导癌细胞凋亡的方法和应用
WO2009146216A2 (en) 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
EA019263B1 (ru) 2008-04-18 2014-02-28 Ритэ Фамэсутикл, Инк. Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
US7915402B2 (en) 2008-04-18 2011-03-29 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
CN104250280A (zh) * 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
ES2449396T3 (es) 2008-07-22 2014-03-19 Trustees Of Dartmouth College Cianoenonas monocíclicas y métodos de uso de las mismas
WO2010132479A2 (en) 2009-05-11 2010-11-18 Cytotech Labs, Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
US20110020914A1 (en) * 2009-07-24 2011-01-27 Novus International Inc Methods for enhancing growth of organisms in an aqueous growth medium
SG10202010355PA (en) * 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
EP4176871A1 (en) 2011-10-03 2023-05-10 Canqura Oncology Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrphobic molecules in fields of medicine including cancer treatment and food related compounds
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
KR102279451B1 (ko) 2013-04-08 2021-07-19 버그 엘엘씨 코엔자임 q10 병용 요법을 이용한 암 치료
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
MX2019005401A (es) 2016-11-08 2019-08-05 Reata Pharmaceuticals Inc Metodos para tratar el sindrome de alport con bardoxolona metilo o analogos de la misma.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2039229T3 (es) * 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
WO1989011862A1 (en) * 1988-05-31 1989-12-14 Biotechnology Australia Pty. Ltd. Actions of hormones
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5077057A (en) * 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity

Also Published As

Publication number Publication date
DE69219600T2 (de) 1997-10-02
KR100227302B1 (ko) 1999-11-01
ES2103946T3 (es) 1997-10-01
US5603958A (en) 1997-02-18
CA2103447A1 (en) 1992-12-01
NO934315L (no) 1994-01-26
FI935314A (fi) 1993-11-29
WO1992021331A1 (en) 1992-12-10
FI110408B (fi) 2003-01-31
NO306539B1 (no) 1999-11-22
AU1925192A (en) 1993-01-08
CA2103447C (en) 1999-03-16
SE9101665L (sv) 1992-12-01
FI935314A0 (fi) 1993-11-29
EP0587659B1 (en) 1997-05-07
ATE152620T1 (de) 1997-05-15
SE9101665D0 (sv) 1991-05-31
JPH07500084A (ja) 1995-01-05
AU680807B2 (en) 1997-08-14
SE502569C2 (sv) 1995-11-13
EP0587659A1 (en) 1994-03-23
DE69219600D1 (de) 1997-06-12

Similar Documents

Publication Publication Date Title
NO934315D0 (no) Farmas!ytisk b{rer
MY118371A (en) Tetrahydrolipstatin containing compositions
DE69627835D1 (de) Feste pharmazeutische zusammensetzung aus nanopartikeln
HUP9802828A2 (hu) Belélegezhető vivőanyag szabályozott hatóanyag-leadású gyógyszerkészítményekhez
ES2243229T3 (es) Formulaciones de particulas de hidrogel.
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
HUP0104230A2 (hu) Eljárás inhalációs adagolásra alkalmas hatóanyagszemcsék szuszpenzióinak előállítására
ES2187201T3 (es) Empleo de esteroles y de esterolesteres a nanoescala.
CA2231195A1 (en) Sustained release matrix for high-dose insoluble drugs
TR200100144T2 (tr) Farmasötik aerosol formülasyonu
ATE321532T1 (de) Pharmazeutische zubereitungen und verfahren zu deren lokalen verabreichung
SE0002643L (sv) Inhalationsberedningar innehållande mikropartiklar
CA2180816A1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2193337A1 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients
HUP0302311A2 (hu) Gyógyászati aeroszol-készítmények
ATE232100T1 (de) Gegen magensaft geschützte omeprazol- mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
AR008886A1 (es) Uso de un inhibidor h+,k+-atpasa en la fabricacion de un medicamento para el tratamiento de polipos nasales, del sindrome de widal, uso de dicho inhibidor y un glucocorticoide para la fabricacion de una formulacion farmaceutica y formulacion farmaceutica para administracion simultanea
IL152074A0 (en) Pharmaceutical preparations and their manufacture
DE69622739D1 (de) Pharmazeutische zubereitung mit schneller freisetzung
AU2923389A (en) A pharmaceutical composition
ES2069880T3 (es) Composicion farmaceutica.
DE69222295D1 (de) Pulverförmige pharmazeutische Zusammensetzung
BR9806303A (pt) Sistema de distrituição de droga termoformado, e, unidade de dosagem
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees